H. D. Becker

P05.19.A CLINICAL OUTCOME OF BIOMARKER-GUIDED THERAPIES IN ADULT NEURO-ONCOLOGY PATIENTS: AN UPDATE FROM THE TÜBINGEN MOLECULAR TUMOR BOARD COHORT

David Rieger, H. D. Becker, Barbara Walter, Lorenz Doerner et autres

Abstract BACKGROUND Molecular profiling and target decision in the Molecular Tumor Board (MTB), within structured networks such as the Centers for Personalized Medicine (CPM), have broadened therapeutic options for neuro-oncology patients. Here, we provide an updated analysis of the Tübingen MTB cohort …

us, de (code pays fourni par la source)

P02.12.A DISTINCT MODULATION OF METABOLISM AND GLIOMA-ASSOCIATED MICROENVIRONMENT BY DEXAMETHASONE AND BEVACIZUMAB

L Maise, F Krautwurst, S Surender, Laimdota Zizmare et autres

Abstract BACKGROUND Glioblastomas are aggressive primary tumors of the central nervous system with limited registered therapeutic options. Peritumoral vasogenic or treatment-associated edema —commonly observed after radiation or immunotherapy—poses a significant clinical burden in glioblastoma patients. Dexamethasone (DEXA), a synthetic glucocorticoid, is commonly …

de (code pays fourni par la source)

P02.13.B MAGNETIC NAVIGATION OF IMMUNOBOTS TO ORTHOTOPIC EXPERIMENTAL GLIOMA MODULATES THE GLIOMA-ASSOCIATED MICROENVIRONMENT

H. D. Becker, Nihal Olcay Dogan, S Surender, Z I Erenoglu et autres

Abstract BACKGROUND Glioblastomas are primary tumors of the central nervous system with a poor prognosis. They are characterized by deep infiltration into the surrounding brain parenchyma and an immunosuppressive tumor microenvironment, both of which pose significant challenges to current therapeutic strategies. Various …

de, tr (code pays fourni par la source)

JS04.7.A IDENTIFICATION OF BCL FAMILY MEMBERS AS MODULATORS OF REGORAFENIB EFFICACY IN EXPERIMENTAL GLIOMA

L A Haeusser, H. D. Becker, Laurence Kuhlburger, Márcia María Fontão Zago et autres

Abstract BACKGROUND Glioblastoma are aggressive primary tumors of the central nervous system with limited systemic treatment options. Regorafenib, a multi-tyrosine kinase inhibitor, demonstrated improved median overall survival in the phase 2 REGOMA trial for progressive glioblastoma, compared to the control arm with …

de (code pays fourni par la source)

Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma

L A Haeusser, H. D. Becker, Laurence Kuhlburger, M A Zago et autres

BACKGROUND: Registered systemic treatment options for glioblastoma patients are limited. The phase II REGOMA trial suggested an improvement of median overall survival in progressive glioblastoma by the multi-tyrosine kinase inhibitor regorafenib. This has not been confirmed by GBM AGILE. So far, regorafenib …

de, us (code pays fourni par la source)

P10.04.B LONGITUDINAL [18F ]FET-PET-BASED IMAGING AND PROFILING OF PDGFB-DRIVEN EXPERIMENTAL GLIOMA USING THE RCAS-TVA SYSTEM

H. D. Becker, Salvador Castaneda Vega, K Patzwaldt, Justyna M. Przystal et autres

Abstract BACKGROUND Glioblastoma are aggressive and incurable primary tumors of the central nervous system. As patients present with already established tumors, longitudinal imaging by MRI and [18F]FET-PET in human glioblastoma for characterizing temporal and spatial metabolic alterations is only possible to characterize …

de, us (code pays fourni par la source)

P10.29.A FUNCTIONALLY INSTRUCTED COMBINATION-TREATMENTS INVOLVING REGORAFENIB IN EXPERIMENTAL GLIOMA

L A Haeusser, Laurence Kuhlburger, Barbara Walter, H. D. Becker et autres

Abstract BACKGROUND Glioblastoma are incurable primary tumors of the central nervous system. The standard of care for newly diagnosed glioblastoma outside clinical trials includes a combination of radiation therapy, alkylating chemotherapy and tumor-treating fields. Yet, for progressive glioblastoma, only lomustine is registered …

de (code pays fourni par la source)

Funktion und Regeneration des exokrinen Pankreas nach Transplantatpankreatitis

F. Pfeffer, M. B�sing, H. D. Becker, M. Nauck et autres

de (code pays fourni par la source)

Stellenwert der einzeitigen chirurgischen Therapie bei diffuser Peritonitis (Relaparotomie „on demand“): eine unizentrische Analyse

Stephan Pauly, Felix Schulze, O. Horstmann, H. D. Becker et autres

Hintergrund: Die diffuse Peritonitis ist ungeachtet moderner chirurgischer und intensivmedizinischer Therapieverfahren eine Erkrankung mit hoher Morbidität und Mortalität. Ziel dieser Arbeit war es, im eigenen Krankengut den Stellenwert der Relaparotomie „on demand“ (ROD) bei Patienten mit diffuser Peritonitis kritisch zu evaluieren. Patienten …

de (code pays fourni par la source)

Impressum

W. Kozuschek, F. Pfeffer, M. Büsing, U. Adam et autres

Insulinsekretion und Glukosemetabolismus nach Pankreastransplantation

Michael A. Nauck, F. Pfeffer, M. B uuml sing, C. Nauck et autres

Nach Pankreastransplantation steht Typ-1-Diabetikern wieder eine Quelle nahezu physiologisch regulierter Insulinsekretion zur Verfügung. Dies führt auch ohne Diät zur vollständigen Normalisierung der Plasmaglukosewerte im Tagesprofil und der glykierten Hämoglobinwerte. Auch nach oraler Glukosebelastung findet sich meistens eine normale orale Glukosetoleranz (WHO-Kriterien), bei …

de (code pays fourni par la source)

Die Spondylodiszitis bei kyphotischer Deformität der Spondylitis ankylosans und ihre Ausheilung durch dorsale Korrekturosteotomien

H. Hehne, H. D. Becker, K Zielke

Out of 144 patients with kyphotic deformities in Ankylosing spondylitis 33 (23%) had 45 disco-vertebral lesions of the spondylodiscitic type. They were characterized by osteolyses, scleroses and absence of syndesmophytes. 5 had additional arch fractures. All were localized in or below the …

de (code pays fourni par la source)